DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) Files An 8-K Results of Operations and Financial ConditionItem 9.01 – Results of Operations and Financial Condition
On August 14, 2017, Diffusion Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for its second quarter ended June 30, 2017. A copy of that press release and the attached financial schedules are attached as Exhibit99.1 to this report and incorporated herein by reference.
The information in this report (including Exhibit99.1) is being furnished to Item 9.01 and shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits.
|
ExhibitNumber |
Description |
|
99.1 |
Press release dated August 14, 2017, announcing financial results for the second quarter ended June 30, 2017. |
Diffusion Pharmaceuticals Inc. ExhibitEX-99.1 2 ex99-1.htm EXHIBIT 99.1 ex99-1.htm Exhibit 99.1 Diffusion Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update CHARLOTTESVILLE,…To view the full exhibit click here
About DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN)
Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company’s Diffusion’s technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.